-
Jan 21, 2025 | 
nature.com | Fatima Cardoso |Heather L. McArthur |Javier Cortés |Nadia Harbeck |Melinda L. Telli |David W. Cescon | +3 more
AbstractAddition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer remains unclear.
-
Aug 18, 2024 | 
cancernetwork.com | Joyce O’Shaughnessy |Heather L. McArthur |Javier Cortés |Yeon Hee Park
BackgroundKEYNOTE-756 is a global phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo plus endocrine therapy (ET) in patients with early-stage high-risk estrogen receptor–positive (ER+)/HER2-negative breast cancer. Here, we report primary pathologic complete response (pCR) results and residual cancer burden (RCB) outcomes.
-
Jul 29, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
In their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.
-
Jul 29, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
OpinionVideoJuly 29, 2024Author(s):The key opinion leaders discuss the current unmet needs in the management of HR+/HER2- metastatic breast cancer and explore potential future directions and strategies that may lead to improved patient outcomes. Looking ahead, what are the key remaining unmet needs and future directions to improve outcomes for HR+/HER2- mBC patients with ESR1 and other mutations driving endocrine resistance?
-
Jul 22, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.
-
Jul 22, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.
-
Jul 8, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
Author(s):Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario. How does this truncal vs acquired distinction impact treatment strategies for ESR1 mutation-positive disease? What criteria are used to classify ESR1 mutations as truncal vs acquired?
-
Jul 8, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
Author(s):The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.
-
Jul 8, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
Author(s):Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice. Please provide some background on the EMERALD trial evaluating elacestrant in HR+ HER2- mBC as well as subgroup data in patients with visceral metastases (Shah et al. J Clin Oncol.
-
Jun 24, 2024 | 
onclive.com | Virginia Kaklamani |Heather L. McArthur
OpinionVideoJune 24, 2024Author(s):The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer. What are the challenges and limitations of current strategies to overcome or delay the emergence of ESR1 mutations and endocrine resistance?
